Biotechnology Press Release
|05/07/2020 - 10:12||
SELLAS to Present at UBS Virtual Global Healthcare Conference
SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel cancer immunotherapies for a broad range of cancer indications, today announced that Angelos Stergiou, M.D., ScD h.c., President and Chief Executive Officer of SELLAS, will present a corporate overview at the UBS Virtual Global Healthcare Conference on Monday, May 18, 2020 at 4:40 pm EDT (1:40 pm PDT).
|SELLAS Life Sciences|
|05/07/2020 - 09:13||
Research Brief: Engineering natural selection in microbes has implications for biofuel production, addressing antibiotic resistance
Scientists who study adaptation — or edit the genes of organisms — know the limitations inherent in conventional approaches to mutation that offer little opportunity to target individual genes without altering others as well.
|05/07/2020 - 08:53||
JAX, UConn Health partnering to train the next generation of genomic scientists
JAX delivers hands-on and immersive educational programs in Maine, Connecticut and across the globe. Sign up for event updates and information.
|05/07/2020 - 08:05||
Roslin broadens research tackling Covid-19
Roslin work includes investigating the coronavirus impact, origin, treatment pathways and tracking Covid-19.
|05/07/2020 - 07:09||
OPTI Medical Systems Receives US FDA Emergency Use Authorization for Its OPTI SARS-CoV-2 RNA PCR Test Kit for Detection of the Virus Causing COVID-19
ROSWELL, Ga., and WESTBROOK, Maine, May 7, 2020—OPTI Medical Systems, Inc., a subsidiary of IDEXX Laboratories, Inc.
|05/07/2020 - 06:41||
Thermo Fisher Scientific Announces SARS-CoV-2 GlobalAccess Sequencing Program
Company to provide 50 Ion Torrent Genexus Systems for consortia members at a subsidized price to support global COVID-19 research.
|Thermo Fisher S...|
|05/07/2020 - 03:06||
Quadram researchers working on COVID-19 vaccine join WHO expert groups
Quadram Institute researchers who are working on a new drug delivery method for a COVID-19 vaccine have joined World Health Organization (WHO) expert advisory groups tackling the coronavirus.
|05/07/2020 - 02:59||
ANU Socially Responsible Investment policy 2019 Report
The Australian National University adopted a Socially Responsible Investment (SRI) Policy in July 2013. This policy contained clear Environmental, Social and Governance (ESG) benchmarks, becoming at the time one of only a handful of Universities worldwide who use responsible investment to advance its objectives on social and sustainability issues.
|05/06/2020 - 14:25||
Leading Independent Proxy Advisory Firms Recommend Ritter Pharmaceuticals Shareholders Vote in Favor of its Merger and Each of the Merger Proposals
Leading Independent Proxy Advisory Firms Recommend Ritter Pharmaceuticals Shareholders Vote in Favor of its Merger and Each of the Merger Proposals.
|05/06/2020 - 13:56||
American Diabetes Association Welcomes Regeneron to Initiative to Help Prevent Vision Loss in People with Diabetes
American Diabetes Association® Welcomes Regeneron to Initiative to Help Prevent Vision Loss in People with Diabetes.
|05/06/2020 - 12:24||
A drug lead molecule studied by Viikki Biochemists may help in the fight against COVID-19
Since 2014, Tenure Track Group Leader Ville Paavilainen’s laboratory has been investigating a molecule, which now shows promise in targeting the new coronavirus. In the best-case scenario, this work could lead to development of a new drug to help alleviate symptoms and prevent progression of COVID-19.
|05/06/2020 - 12:20||
BioMarin to Participate in Two Upcoming Virtual Investor Conferences
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that management will participate in the Bank of America Global Research Health Care Conference on May 14, 2020 at 2:20pm ET and the RBC Capital Markets Global Healthcare Conference on May 19, 2020 at 1:55pm ET. An audio webcast of the presentation will be available live. You can access the webcast at: https://investors.biomarin.com/. An archived version of the remarks will also be available through the Company's website for a limited time following the conference.
|05/06/2020 - 09:02||
EXIM Launches Strengthening American Competitiveness Initiative
Initiative Focuses on Supporting Transformative U.S. Exports and Jobs, Advancing America’s Comparative Leadership in the World, and Competing with China in the Global Marketplace.
|05/06/2020 - 07:03||
Bariatric Surgery Devices Market Research Report, Size, Share, Trends and Forecast to 2025
The global bariatric surgery devices market grew at a CAGR of around 7% during 2014-2019. Looking forward, the market is expected to continue its moderate growth during the next five years., according to a new report by IMARC Group.
|05/06/2020 - 06:47||
Rapid COVID-19 Genome Sequencing Aids Outbreak Investigations
New Ion AmpliSeq SARS-CoV-2 Research Panel, now optimized for the Ion Torrent Genexus System*, assists with contact tracing to identify coronavirus hot spots.
|Thermo Fisher S...|
|05/06/2020 - 05:13||
BrightInsight and CSL Behring Announce Global Digital Health Partnership to Improve Treatment Experience for Patients with Rare Diseases
BrightInsight, Inc., the provider of the leading regulated IoT platform for biopharma and medtech, and CSL Behring, a leading biotechnology company, today announced a global digital health partnership to provide digitally-enhanced treatment experiences and regulated digital health offerings to support CSL Behring therapies. CSL Behring selected the regulated BrightInsight Platform to manage and support its growing digital health portfolio of solutions focused on enhancing the treatment experiences of patients with rare and serious diseases.
|05/06/2020 - 04:46||
BAUSCH + LOMB LICENSES EXCLUSIVE RIGHTS FROM STADA AND XBRANE TO A BIOSIMILAR CANDIDATE FOR LUCENTIS (RANIBIZUMAB) IN THE UNITED STATES AND CANADA
BRIDGEWATER, NJ., BAD VILBEL, Germany, and SOLNA, Stockholm, May 06, 2020 - Bausch + Lomb, a leading global eye health business of Bausch Health Companies Inc.
|Bausch and Lomb|
|05/06/2020 - 03:23||
Enanta Announces Results of INTREPID Study of EDP-305 for the Treatment of Primary Biliary Cholangitis
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced topline results from its INTREPID Phase 2 study of EDP-305, a Farnesoid X receptor (FXR), in subjects with primary biliary cholangitis (PBC).
|05/06/2020 - 02:35||
Lupin Launches Jan Kovid Helpline for Mumbai Citizens
Mumbai, India, May 6, 2020: Pharma major Lupin Limited (Lupin) today announced the launch of the ‘Jan Kovid’ Helpline (1800-572-6130) under the tagline ‘Mann Ka Swaasthya, Tann Ki Suraksha’ for the residents of Mumbai.
|05/06/2020 - 01:22||
First Patient Dosed in FDA-Approved Phase III Lenzilumab Study for COVID-19
First US randomized, double-blind, placebo-controlled, multi-center, Phase III study with an anti-GM-CSF monoclonal antibody which, if successful, may lead to lenzilumab product approval for COVID-19
|05/06/2020 - 00:19||
Exelixis to Webcast Fireside Chats as Part of Virtual Investor Conferences in May
Exelixis, Inc. (Nasdaq: EXEL) today announced that members of Exelixis’ management team will participate in fireside chats at the following virtual investor conferences in May:
|05/05/2020 - 15:29||
Adaptive Biotechnologies and Microsoft launch virtual ImmuneRACE study to inform novel COVID-19 diagnostics to address unmet needs in testing
LabCorp, through its Covance drug development business, will provide a safe, in-person COVID-19 sample collection service from the convenience of patients’ homes.
|05/05/2020 - 13:57||
Intensive farming increases risk of epidemics, warn scientists
Research from the University of Sheffield and the University of Bath has discovered how a common pathogen is able to infect both cattle and humans The bacterium Campylobacter jejuni is a common cause of food poisoning and is often resistant to antibiotics The research found that the bacterium is able to infect more than one species because of its ability to transfer genes and adapt quickly to new host environments.
|05/05/2020 - 12:13||
Rgenta Therapeutics recipient of the Serviers 2020 LabCentral Golden Ticket
Paris (France) and Cambridge (U.S.), May 5, 2020 – Servier has awarded the 2020 Servier Golden Ticket at LabCentral to Rgenta Therapeutics, a new biotechnology company focusing on developing RNA-targeting medicines for historically undruggable disease-relevant targets. The award will help Rgenta Therapeutics advance the company’s pursuit of high-value oral, small molecule RNA targets in a range of therapeutic areas, including oncology and neurology.
|05/05/2020 - 12:12||
David Trulio Appointed as Counselor to the Chairman and Senior Vice President for EXIMs New Program on China and Transformational Exports
Trulio Joins Senior Management Team to Lead One of the Most Significant Programs in EXIM’s 86-year History.